All lectures take place at 3647 Peel, Don Bates Seminar Room 101 until noted otherwise.
PLEASE NOTE THAT SEMINAR TIMES MAY VARY, SO BE SURE TO CHECK EACH INDIVIDUAL LISTING CAREFULLY
Tuesday November 7, 2017 @ 12:00 PM
Bloomfield Lecture Hall, Lady Davis Institute, Jewish General Hospital
Dr. Deborah Zarin
ClinicalTrials.gov: A window into the Clinical Research Enterprise
Deborah A. Zarin, M.D. has been the Director of ClinicalTrials.gov since 2005. Dr. Zarin has played a major role in the development and implementation of the key legal and policy mandates for clinical trial reporting. As part of that process, Dr. Zarin provided the scientific leadership for the creation of the first structured public database for the reporting of summary trial results.
Dr Zarin’s recent research has been on the quality of trial reporting, as well as issues in the design and analysis of clinical trials. Dr. Zarin’s academic interests are in the area of evidence based clinical and policy decision making, as well as clinical trial conduct, analysis and reporting. She is the author of over 80 peer reviewed articles.
Dr. Zarin graduated from Stanford University and received her doctorate in medicine from Harvard Medical School. She completed a clinical decision making fellowship, a pediatric internship, and is board certified in general psychiatry, as well as in child and adolescent psychiatry.
Tuesday April 11, 2017 @ 3:00 PM
Josephine Johnson, LLB, MBHL
Sequencing the Stork: Genomics and the “Good Parent”
Advances in genetic technology promise to provide women, and men, with more information about—and control over—the genetic make-up of their future children. Information and control are highly prized in our culture, and they can offer substantial benefits to prospective parents. But they can also generate new responsibilities, raising the question whether refusing information or refusing control can be consistent with being a “good parent”. In this paper, I explore the idea of the good parent, and discuss how that idea might evolve in response to reproductive uses of genomics.
Friday March 3, 2017 @ 12:00 PM
Seema Shah, PhD
Ethical considerations for Zika virus human challenge trials
Zika virus is an insidious disease that has become a major public health threat around the world. Zika virus can cause devastating neurological damage in infants and adults in some cases, and may have other effects that are not yet known. Although there are ongoing public health efforts to stem the disease, there are no treatments or vaccines approved for Zika virus. There is therefore urgent need to develop biomedical interventions against Zika virus. One powerful tool for testing treatments and vaccines for infectious diseases is human challenge research, in which volunteers are purposefully exposed to pathogens in order to answer research questions more quickly, rigorously, and efficiently. Despite the fact that challenge studies have a long history, bioethicists have only recently analyzed when they are justifiable. The ethics literature provides limited guidance for Zika virus human challenge studies because scholars focus on human challenge research on diseases that are well-understood and can be treated effectively. In this talk, I will provide a framework of ethical considerations for Zika virus human challenge trials and address the question of whether they can be ethically justified.
[PDF icon] bioe_seminar_poster_2.pdf
Studies of Translation, Ethics and Medicine (STREAM) Seminar
Tuesday, October 4, 2016 1 PM
Mark Yarborough, PhD
Everyone acknowledges the need for biomedical research to enjoy the public’s trust that it continuously solicits and receives. An ethical precondition of soliciting trust is knowing the extent to which that trust is deserved. What makes biomedical research deserving of the public trust requires in-depth attention. This session will review three different criteria of trustworthiness in research - reliability, social value, and ethical conduct - to explore the extent to which the biomedical research enterprise warrants public trust.
May 13th, 2016 - 10:00 AM
Adelaide Doussau de Bazignan, MD, PhD
"Is it ethically justified to increase the number of patients treated with experimental drugs in cancer placebo controlled trials?"